Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

BRAF is a kinase enzyme that helps control cell growth and signaling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. Product approvals by regulatory bodies in various regions across the globe are expected to drive growth of the market during the forecast period. For instance, in July 2020, Roche announced that the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.

BRAF Kinase Inhibitors Market – Impact of Coronavirus (Covid-19) Pandemic

As the novel coronavirus has spread across the globe, it has created profound disruption across communities, hospitals, and other healthcare settings, and the way it works. Product development has experienced disruption, as researchers have to adjust to remote work environments and lab capacity is reduced. Clinical trials are also being severely affected with disruptions in both new enrollment and in keeping existing patients on therapies. According to the clinicaltrial.gov, as of April 2020, there were more than 2,850 trials and approximately 900,000 patients enrolled at trial sites in regions that were in partial or complete lockdown due to COVID-19 restrictions. The R&D labs are operating at below 50% of normal capacity.

The BRAF kinase inhibitors market is estimated to be valued at US$ 924.8 million in 2020 and is expected to exhibit a CAGR of 8.6% during the forecast period (2020-2027).

Figure 1. Global BRAF Kinase Inhibitors Market Share (%) Analysis, By Drug 2020

BRAF Kinase Inhibitors  | Coherent Market Insights

The robust pipeline for treatment of metastatic cancers and increasing prevalence of cancer are expected to boost growth of the BRAF kinase inhibitors market

Several companies have ongoing clinical trials of BRAF kinase inhibitors drugs. The robust pipeline of BRAF kinase inhibitor drugs is expected to significantly drive growth of the global BRAF kinase inhibitors market in the near future. For instance, in June 2020, BeiGene, Ltd., a commercial-stage biotechnology company and SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the presentation of preclinical data and provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene’s investigational RAF dimer inhibitor, lifirafenib, with SpringWorks’ investigational MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors harboring mutations in the MAPK pathway, including those with RAS mutations.

Furthermore, BRAF kinase inhibitors market is expected to witness high growth over the forecast period, owing to increasing incidence and prevalence of metastatic cancer. For instance, according to the Centers for Disease Control and Prevention provided data for 2012 to 2016, around 77,698 new cases of melanoma cancer (45,854 among men and 31,845 among women) were diagnosed every year in the U.S. Moreover, the American Cancer Society estimated that around 100,350 new cases of melanoma will be diagnosed and around 6,850 deaths are estimated to occur due to melanoma in the U.S. in 2020. Hence, such drivers are expected to positively impact the global BRAF kinase inhibitors market growth.

request-sample

BRAF Kinase Inhibitors Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 924.8 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR:

8.6%

2027 Value Projection: US$ 1,651.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of APAC
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug: Vemurafenib, Dabrafenib, Lifirafenib, Encorafenib.
  • By Indication: Metastatic Melanoma, Metastatic Lung Cancer, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Growth Drivers:
  • Robust pipeline for treatment of metastatic cancers
  • Increasing prevalence of cancer
Restraints & Challenges:
  • High cost of cancer treatment
  • Availability of alternative treatment

BRAF Kinase Inhibitors Market – Restraints

Medications and surgical operations are used to prevent or slow down further damage from occurring. Extensive R&D activities and manufacturing makes the drugs very expensive, which is expected to hamper the BRAF kinase inhibitors market growth over the forecast period. For instance, according to data published in National Center for Biotechnology Information (NCBI), by Experimental Hematology & Oncology, by year 7 of metastatic cancer, the cumulative costs per month were US$ 4,281 for ipilimumab, compared to US$ 8,920 for dabrafenib, US$ 10,211 for trametinib, US$ 11,002 for vemurafenib, and US$ 19,132 for dabrafenib + trametinib combination therapy.

BRAF Kinase Inhibitors Market – Regional Analysis

North America is estimated to hold the dominant position in 2020 in the global BRAF kinase inhibitors market. Increasing number of product approvals by the regulatory authorities is a major factor that propels growth of the North America BRAF kinase inhibitors market. For instance, in July 2020, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab (Tecentriq) plus the MEK inhibitor cobimetinib (Cotellic) and the selective BRAF kinase inhibitor vemurafenib (Zelboraf) for the treatment of patients with advanced BRAF V600 mutation–positive melanoma. The approval is based on results from IMspire150, a multicenter, double-blind, placebo-controlled randomized phase III study.

Moreover, Europe BRAF kinase inhibitors market is also expected to gain momentum over the forecast period. For instance, in September 2018, Pierre Fabre announced that the European Commission (EC) granted marketing authorization for the combination of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test. The EC decision is applicable to all 28 European Union (EU) member states and Liechtenstein, Iceland, and Norway.

Figure 2. Global BRAF Kinase Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

BRAF Kinase Inhibitors  | Coherent Market Insights

BRAF Kinase Inhibitors Market - Competitive Landscape

Key players operating in the global BRAF kinase inhibitors market include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.

BRAF is a kinase enzyme that helps control cell growth and signalling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins may help keep cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. Two compounds (vemurafenib and dabrafenib) have achieved approval by the Food and Drug Administration (FDA) for the treatment of metastatic and unresectable BRAF-mutated melanomas.

Market Dynamics

Key players in the BRAF kinase inhibitors market are focusing on obtaining patents, which is expected to create more opportunities for BRAF kinase inhibitor drugs manufacturers in the emerging economies. For instance, in September 2016, Novartis International AG secured an Indian patent for its skin cancer (melanoma) drug Tafinlar, which is used for the treatment of metastatic melanoma, the most serious and life-threatening type of skin cancer that is associated with low survival rates.

However, one of the challenges in BRAF kinase inhibitors market is patient adherence. Due to the high cost of BRAF kinase inhibitor drugs, patients are shifting from the actual treatment regime to alternatives of cancer treatments. Alternative methods available for cancer treatments is expected to hinder growth of the BRAF kinase inhibitors market in the near future. For instance, metastatic cancer requires systemic therapy or medications given through mouth or injected into the bloodstream to reach cancer cells throughout the body such as chemotherapy or hormone therapy. Other treatments may include immunotherapy, radiation therapy, surgery or a combination of these.

Key features of the study:

  • This report provides in-depth analysis of the global BRAF kinase inhibitors market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global BRAF kinase inhibitors market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global BRAF kinase inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for BRAF kinase inhibitors market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global BRAF Kinase Inhibitors Market, By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
  • Global BRAF Kinase Inhibitors Market, By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
  • Global BRAF Kinase Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global BRAF Kinase Inhibitors Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug:
        • Vemurafenib
        • Dabrafenib
        • Lifirafenib
        • Encorafenib
      • By Indication:
        • Metastatic Melanoma
        • Metastatic Lung Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug:
        • Vemurafenib
        • Dabrafenib
        • Lifirafenib
        • Encorafenib
      • By Indication:
        • Metastatic Melanoma
        • Metastatic Lung Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug:
        • Vemurafenib
        • Dabrafenib
        • Lifirafenib
        • Encorafenib
      • By Indication:
        • Metastatic Melanoma
        • Metastatic Lung Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug:
        • Vemurafenib
        • Dabrafenib
        • Lifirafenib
        • Encorafenib
      • By Indication:
        • Metastatic Melanoma
        • Metastatic Lung Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug:
        • Vemurafenib
        • Dabrafenib
        • Lifirafenib
        • Encorafenib
      • By Indication:
        • Metastatic Melanoma
        • Metastatic Lung Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
      • By Drug:
        • Vemurafenib
        • Dabrafenib
        • Lifirafenib
        • Encorafenib
      • By Indication:
        • Metastatic Melanoma
        • Metastatic Lung Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Hoffmann-La Roche AG*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Novartis International AG
    • Pfizer, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Product Launches
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • Treatment Evolution
    • Pipeline Analysis
    • Reimbursement Scenario
  4. Global BRAF Kinase Inhibitors Market - Impact of Coronavirus (Covid-19) Pandemic
    • Supply Side And Demand Side Analysis
    • Overall Impact
    • Impact on Research and Development
  5. Global BRAF Kinase Inhibitors Market, By Drug, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Vemurafenib       
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Dabrafenib
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Lifirafenib
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Encorafenib
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global BRAF Kinase Inhibitors Market, By Indication, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Metastatic Melanoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Metastatic Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global BRAF Kinase Inhibitors Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global BRAF Kinase Inhibitors Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Company Profiles
      • Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 34 market data tables and 32 figures on "Global BRAF Kinase Inhibitors Market” - Forecast to 2027”

Frequently Asked Questions

The BRAF kinase inhibitors market is expected to register a CAGR of market is 8.6% during the forecast period (2020-2027).
The value of BRAF kinase inhibitors market is estimated to be US$ 924.8 million in 2020.
The prominent players in the global BRAF kinase inhibitors include market F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.
The BRAF kinase inhibitors market is expected to be valued at US$ 1,651.3 million in 2027.
North America is the major region in the BRAF kinase inhibitors market.
The increasing number of product approvals, launches, increasing prevalence of cancer, and robust pipeline for treatment of metastatic cancers are expected to drive growth of the BRAF kinase inhibitors market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner